A. Hilary Calvert

8.8k total citations · 2 hit papers
75 papers, 5.9k citations indexed

About

A. Hilary Calvert is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, A. Hilary Calvert has authored 75 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 33 papers in Oncology and 18 papers in Pathology and Forensic Medicine. Recurrent topics in A. Hilary Calvert's work include Biochemical and Molecular Research (16 papers), Cancer therapeutics and mechanisms (16 papers) and Chemotherapy-induced organ toxicity mitigation (16 papers). A. Hilary Calvert is often cited by papers focused on Biochemical and Molecular Research (16 papers), Cancer therapeutics and mechanisms (16 papers) and Chemotherapy-induced organ toxicity mitigation (16 papers). A. Hilary Calvert collaborates with scholars based in United Kingdom, United States and Canada. A. Hilary Calvert's co-authors include David R. Newell, Zahid H. Siddik, Martin Gore, E. Wiltshaw, Lindsey Gumbrell, Frances Boxall, Séamus O’Reilly, Matthew Burnell, Ian Judson and Nicola J. Curtin and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

A. Hilary Calvert

73 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

1989 1.5k citations A. Hilary Calvert, David R. Newell et al. Journal of Clinical Oncology profile →
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II

1982 408 citations A. Hilary Calvert, David R. Newell et al. Cancer Chemotherapy and Pharmacology profile →

Peers

Countries citing papers authored by A. Hilary Calvert

Since Specialization

Citations

This map shows the geographic impact of A. Hilary Calvert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Hilary Calvert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Hilary Calvert more than expected).

Fields of papers citing papers by A. Hilary Calvert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Hilary Calvert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Hilary Calvert. The network helps show where A. Hilary Calvert may publish in the future.

Co-authorship network of co-authors of A. Hilary Calvert

This figure shows the co-authorship network connecting the top 25 collaborators of A. Hilary Calvert. A scholar is included among the top collaborators of A. Hilary Calvert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Hilary Calvert. A. Hilary Calvert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Expert consensus on best content of a robotic surgical curriculum: a systematic review 2025 ·Journal of Robotic Surgery ·(unknown), (unknown), (unknown), A. Hilary Calvert, Kenneth Walker, Kim Walker, Angus Watson	0
2	Design and conduct of early clinical studies of two or more targeted anticancer therapies: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies 2013 ·European Journal of Cancer ·Lesley Seymour, A. Hilary Calvert, Marinus W. Lobbezoo, Elizabeth A. Eisenhauer, Giuseppe Giaccone	5
3	Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT) 2007 ·European Journal of Cancer ·Christopher M. Booth, A. Hilary Calvert, Giuseppe Giaccone, Marinus W. Lobbezoo, Lesley Seymour, Elizabeth A. Eisenhauer	60
4	Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism 2002 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Godefridus J. Peters, Harold H.J. Backus, (unknown), Baukelien van Triest, Giovanni Codacci-Pisanelli, C.L. van der Wilt, Kees Smid, John Lunec, A. Hilary Calvert, Sharon Marsh, Howard L. McLeod, Elisabeth Bloemena, Sybren L. Meijer, Gerrit Jansen, C.J. van Groeningen, Herbert M. Pinedo	328
5	Effect of temozolomide on central nervous system relapse in patients with advanced melanoma 2002 ·Melanoma Research ·(unknown), Yvonne Summers, A. Hilary Calvert, Gordon Rustin, (unknown), N. Thatcher, Mark R. Middleton	87
6	Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro 2001 ·British Journal of Cancer ·Karen J. Bowman, David R. Newell, A. Hilary Calvert, Nicola J. Curtin	109
7	Novel Benzimidazole and Quinazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP‐ribose)polymerase* 1996 ·Pharmacy and Pharmacology Communications ·Roger J. Griffin, Sheila Srinivasan, Alex W. White, Karen J. Bowman, A. Hilary Calvert, Nicola J. Curtin, David R. Newell, Bernard T. Golding	9
8	A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve 1996 ·Cancer Chemotherapy and Pharmacology ·Saad Ghazal‐Aswad, A. Hilary Calvert, David R. Newell	38
9	Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer 1996 ·Nature Medicine ·(unknown), A. Hilary Calvert, John Anderson, David E. Neal, John Lunec	239
10	Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer 1995 ·Cancer Chemotherapy and Pharmacology ·Michael Millward, David R. Newell, Kally Yuen, Jane Matthews, Kathryn Balmanno, (unknown), Lindsey Gumbrell, Michael Lind, Fiona Chapman, (unknown), (unknown), Brian M.J. Cantwell, A. Hilary Calvert	18
11	Phase I trial of the anthrapyrazole CI-941: Prospective evaluation of a pharmacokinetically guided dose-escalation 1992 ·European Journal of Cancer ·(unknown), David R. Newell, Lindsey Gumbrell, A. Hilary Calvert, Marien Alet Graham, S.B. Kaye, (unknown)	17
12	Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C-2 position 1990 ·Journal of Medicinal Chemistry ·Leslie R. Hughes, Ann L. Jackman, J.W. Oldfield, (unknown), (unknown), Peter R. Marsham, (unknown), Terence R. Jones, Brigid M. O'Connor, A. Hilary Calvert	57
13	Carboplatin dosage: prospective evaluation of a simple formula based on renal function. breakdown → 1989 ·Journal of Clinical Oncology ·A. Hilary Calvert, David R. Newell, Lindsey Gumbrell, Séamus O’Reilly, Matthew Burnell, Frances Boxall, Zahid H. Siddik, Ian Judson, Martin Gore, E. Wiltshaw	1510
14	Determination of the anthrapyrazole anticancer drug CI-941 in plasma and urine by solid-phase extraction and high-performance liquid chromatography 1989 ·Journal of Chromatography B Biomedical Sciences and Applications ·(unknown), David R. Newell, A. Hilary Calvert	17
15	Quinazoline antifolate thymidylate synthase inhibitors: nitrogen, oxygen, sulfur, and chlorine substituents in the C2 position 1989 ·Journal of Medicinal Chemistry ·Peter R. Marsham, (unknown), Anthony J. Hayter, Leslie R. Hughes, (unknown), (unknown), (unknown), A. Hilary Calvert	8
16	Estimation of the In Vitro and In Vivo Inhibitory Effects of Antifolates upon Thymidylate Synthase (TS) in Whole Cells 1989 ·Advances in experimental medicine and biology ·Geoffrey A. Taylor, A L Jackman, Kathryn Balmanno, L. R. HUGHES, A. Hilary Calvert	12
17	The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients 1989 ·Cancer Chemotherapy and Pharmacology ·(unknown), (unknown), (unknown), A. Hilary Calvert	16
18	High dose carboplatin in the treatment of lung cancer and mesotherlioma: a phase I dose escalation study 1987 ·European Journal of Cancer and Clinical Oncology ·Martin Gore, A. Hilary Calvert, I. E. Smith	58
19	Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin 1987 ·European Journal of Cancer and Clinical Oncology ·David R. Newell, Zahid H. Siddik, Lindsey Gumbrell, Frances Boxall, Martin Gore, Ian E. Smith, A. Hilary Calvert	64
20	Use of a solubilisation procedure in the determination of platinum (Pt) in rodent and human tissues following carboplatin (JM8, CBDCA) administration 1985 ·Proceedings of the American Association for Cancer Research ·Zahid H. Siddik, Frances Boxall, A. Hilary Calvert, Kenneth R. Harrap	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact